Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Halsey Drug

  • News

Executive Summary

Generic firm's Brooklyn plant resumes shipment of its combination acetaminophen, butalbital and caffeine 325 mg/50 mg/40 mg tablet the week of Aug. 23 and expects to resume shipment of two to three additional solid dosage products "shortly," firm reports in an Aug. 26 financial release. Shipment of oxycodone/acetaminophen 5 mg/325 mg and 5 mg/500 mg capsules from its Brooklyn facility resumed in early August. Halsey had suspended shipment of all non-liquid products from the Brooklyn plant under a June 29 consent decree with FDA ("The Pink Sheet" July 5, T&G-11).

Table

View full table

Tags:
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

See All
UsernamePublicRestriction

Register

PS023221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By